The Patent Finder

Terms ending in 2039

GlaxoSmithKline LLC

Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 12,286,472Biopharmaceutical Compositions and Methods for Pediatric Patients
In force
 · High confidence
GlaxoSmithKline Intellectual Property (No.2) LimitedIn forceHigh confidence
US 11,015,180Carboxyesterase Polypeptides for Amide Coupling
In force
 · High confidence
Codexis, Inc.In forceHigh confidence
US 12,576,089Platelet Count-Agnostic Methods of Treating Myelofibrosis
In force
 · Low confidence
GlaxoSmithKline LLCIn forceLow confidence
US D1,042,109Package
In force
 · High confidence
Haleon UK IP LimitedIn forceHigh confidence
US 12,686,702Methods for Purifying Antibodies
In force
 · High confidence
GlaxoSmithKline Intellectual Property Development LimitedIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by GlaxoSmithKline LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited